[PDF] Top 20 Future therapies in multiple sclerosis
Has 10000 "Future therapies in multiple sclerosis" found on our website. Below are the top 20 most common "Future therapies in multiple sclerosis".
Future therapies in multiple sclerosis
... with multiple sclerosis. During those 15 years four therapies have become established for treatment of early relapsing remitting disease and two others have entered the field for treatment of more ... See full document
5
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies
... First-line therapies currently used in the adult population appear to be safe in children with ...second-line therapies used in the adult population have been used in a small number of children with MS and ... See full document
11
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis
... rise, future studies evaluating the collective and relative impact of DMT attri- butes, such as dosing frequency, routes of administration, and safety, may provide more insight into product features affecting ... See full document
10
Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
... Background: Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been ... See full document
9
Clinico radiological dissociation in multiple sclerosis: Future prospects
... [8] McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P., Lublin, F.D., McFarland, H.F., Paty, D.W., Polman, C.H., Reingold, S.C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., van den Noort, S., Wein- ... See full document
7
Multiple Sclerosis: A Review of Existing Therapy and Future Prospects
... of MS is exciting and reassuring. Unfortunately none of these drugs provides a cure for the disease. Whether combination therapy will be additive remains to be seen. For the large number of individuals who are cuffently ... See full document
8
Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
... Objectives: Our aim was to identify the impact of psychosocial predictors, specifically relationship style, depressive symptoms, anxiety symptoms, cognitive impairment, and [r] ... See full document
6
Complementary and alternative medicine in multiple sclerosis
... HOW ARE EVIDENCE-BASED GUIDELINES DEVELOPED? The American Academy of Neurology (AAN) established a strict process to develop evidence- based guidelines. The AAN identifies an important question and then selects a panel ... See full document
6
Disease-modifying therapies in relapsing–remitting multiple sclerosis
... zumab, rituximab, and fingolimod. With alemtuzumab, the greatest risk seems to be the development of autoimmune syndromes. The effects of cladribine, alemtuzumab, and rituximab on the immune system are more long term, ... See full document
9
Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
... these therapies may still occur due to safety considerations or the thresholds which need to be met to qualify for access to second-line ...additional therapies continue to emerge, factors associated with ... See full document
9
Pharmacologic Therapies for Multiple Sclerosis: From injectable to oral agents
... Newer DMTs are oral therapies: Fingolimod, Teriflunomide and dimethyl fumarate. Ongoing research: More oral medications.[r] ... See full document
37
Multiple Sclerosis Drug Discoveries - What the Future Holds
... Multiple Sclerosis is a chronic autoimmune neurological disease affecting up to 2.5 million people worldwide, the majority of whom live in North America and Europe. It is a complex disorder that affects ... See full document
10
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
... B-cell therapies are already in use for a range of rheumatologic and oncologic diseases, the MS community benefits from this existing pool of safety data; such data can be utilized in designing various Phase I/II/ ... See full document
15
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
... In order to study the effect of natalizumab on GM at- rophy avoiding the marked pseudo-atrophy effect of the drug on brain parenchymal volume, we analysed the cor- tical thickness of RRMS patients treated with natalizu- ... See full document
10
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
... emerging therapies (cladribine, alemtuzumab, rituximab, fingolimod, laquinimod, teriflunomide, and dimethyl fumarate) based on phase II/III trials, as well as their use for indications other than MS, will be ... See full document
20
Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1—Mechanisms, Efficacy, and Safety
... During the past 10 years, there has been an evolution in the treatment of relapsing-remitting MS (RRMS), with a rapid in- crease in the number of disease-modifying therapies available (On-line Table ). Since 2004, ... See full document
8
The effect of disease modifying therapies on disability progression in multiple sclerosis: A systematic overview of meta analyses
... modifying therapies (DMT) that modulate, modify, or suppress the immune system are a medication class used to treat people living with multiple sclerosis (MS) (see Supplementary Table 1 for a list of ... See full document
25
Sexual Dysfunction in Iranian Azeri Women With Multiple Sclerosis: Levels and Correlates
... Therefore, future studies are required in this respect, which are suggested to introduce effective interventions in order to improve the sexual function of MS ... See full document
7
Personalized Medicine Toward Multiple Sclerosis;Current Challenges and Future Prospects
... Multiple sclerosis (MS) is an inflammatory chronic au- toimmune disorder of the central nervous system (CNS) with the main specification of demyelination of neurons, resulting from aberrant activation of ... See full document
5
Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment
... Figure 4 Preference for the route and frequency of administration by duration of the current treatment and type of multiple sclerosis. Notes: 1-year sP: patient with 1 year in current [r] ... See full document
12
Related subjects